

Obesity and Reproduction

Neal Mahutte, MD;¹ Carole Kamga-Ngande, MD, PhD;² Arya Sharma, MD;³ Camille Sylvestre, MD²

¹The Montréal Fertility Centre, Montréal, QC

²Department of Obstetrics and Gynecology, University of Montréal, Montréal, QC

³University of Alberta, Edmonton, AB

Reviewed and approved by the Canadian Fertility & Andrology Society Clinical Practice Guideline Committee: William Buckett, MD; Jon Havelock, MD; Kim Liu, MD; Neal Mahutte, MD (Chair); Jason Min, MD; Jeff Roberts, MD; Sony Sierra, MD; Heather Shapiro, MD; Camille Sylvestre, MD.

Abstract

Objective: To provide a comprehensive review and evidence-based recommendations for the delivery of fertility care to women with obesity.

Outcomes: The impact of obesity on fertility, fertility treatments, and both short and long-term maternal fetal outcomes was carefully considered.

Evidence: Published literature was reviewed through searches of MEDLINE and CINAHL using appropriate vocabulary and key words. Results included systematic reviews, clinical trials, observational studies, clinical practice guidelines, and expert opinions.

Values: The Canadian Fertility & Andrology Society (CFAS) is a multidisciplinary, national non-profit society that serves as the voice of reproductive specialists, scientists, and allied health professionals working in the field of assisted reproduction in Canada. The evidence obtained for this guideline was reviewed and evaluated by the Clinical Practice Guideline (CPG) Committee of the CFAS under the leadership of the principal authors.

Benefits, Harms, and Costs: The implementation of these recommendations should assist clinicians and other health care providers in counselling and providing reproductive care to women with obesity.

Validation: This guideline and its recommendations have been reviewed and approved by the membership, the CPG Committee and the Board of Directors of the CFAS.

Sponsors: Canadian Fertility & Andrology Society.

Recommendations: Twenty-one evidence based recommendations are provided. These recommendations specifically evaluate the

impact of obesity on natural fertility, fertility treatments, and maternal-fetal outcomes. Strategies to lose weight and BMI cut-offs are also addressed.

Résumé

Objectif : Présenter une revue exhaustive ainsi que des recommandations fondées sur des données probantes en matière de soins de fertilité offerts aux femmes présentant une obésité.

Résultats : L'incidence de l'obésité sur la fertilité, les traitements de fertilité et les issues maternelles et fœtales à court et à long terme a été analysée avec soin.

Données : Des études publiées récupérées au moyen de recherches dans MEDLINE et CINAHL à l'aide d'une terminologie appropriée et de mots-clés ont été évaluées. Les documents retenus comprenaient des revues systématiques, des essais cliniques, des études observationnelles, des directives cliniques et des opinions d'experts.

Valeurs : La Société canadienne de fertilité et d'andrologie est une organisation multidisciplinaire nationale à but non lucratif qui se veut la voix des spécialistes de la procréation, des scientifiques et des professionnels de la santé alliés qui travaillent dans le domaine de la procréation assistée au Canada. Les résultats obtenus ont été évalués par le Comité des lignes directrices de pratique clinique de la Société canadienne de fertilité et d'andrologie, sous la direction des auteurs principaux.

Avantages, inconvénients, coûts : La mise en œuvre de ces recommandations devrait aider les cliniciens et les autres fournisseurs de soins de santé à offrir du counseling et des soins de fertilité aux femmes qui présentent une obésité.

Validation : Cette directive clinique et les recommandations qu'elle contient ont été révisées et approuvées par les membres de la Société canadienne de fertilité et d'andrologie, ainsi que par son Comité des lignes directrices de pratique clinique et son conseil d'administration.

Commanditaire : Canadian Fertility & Andrology Society.

Recommandations : Vingt et une recommandations fondées sur des données probantes sont proposées. Plus précisément, ces recommandations décrivent les conséquences de l'obésité sur la fertilité naturelle, les traitements de fertilité et les issues maternelles et fœtales. Des stratégies pour la perte de poids et les seuils d'IMC sont aussi abordés.

J Obstet Gynaecol Can 2018;40(7):950–966

<https://doi.org/10.1016/j.jogc.2018.04.030>

Copyright © 2018 Published by Elsevier Inc. on behalf of The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada

This document is based on available evidence to date, often in a rapidly advancing field of study. Recommendations may not reflect emerging evidence and are subject to change. Clinical guidelines are intended as an aid to clinical judgement, and not to replace it. Clinical guidelines do not prevent clinicians from exercising freedom in their good clinical practice, nor relieve them of their responsibility to make appropriate decisions based on their own knowledge and experience.

Table 1. Internationally recognized BMI cut-off values for underweight, normal weight, overweight and obese³

BMI	Category
<18.5	Underweight
18.5–24.9	Normal Weight
25–29.9	Overweight
30–34.9	Obesity Class I
35–39.9	Obesity Class II
≥40	Obesity Class III

BMI: body mass index.

INTRODUCTION

The purpose of this guideline is to provide a framework for the delivery of fertility care to women with obesity. In Canada, as in many other countries, the prevalence of obesity in adults is increasing. More than half of Canadian men and women are overweight, and from 1978 to 2011 the rate of obesity increased from 14 to 26%.¹ Furthermore, the proportion of Canadians who are obese now exceeds the proportion of Canadians who regularly smoke (11%) or drink alcohol to excess (16%).²

The World Health Organization (WHO) defines obesity as abnormal or excessive fat accumulation that impairs health.³ Obesity is most commonly defined using body mass index (BMI). BMI is the weight in kilograms divided by the square of height in metres (kg/M^2). The international cut-off values for defining underweight, normal weight, overweight and obese using BMI are listed in Table 1. It should be noted that other measures of obesity such as waist circumference, waist-to-hip ratio and the Edmonton obesity scoring

system have merit,^{4,5} but that this guideline focuses primarily on BMI as this is the measure most commonly used in the obesity and reproductive medicine literature.

Excessive caloric intake is the fundamental cause of obesity. Globally we are seeing an increase in the consumption of energy-dense foods, and a reduction in physical activity.² The health consequences of this imbalance include cardiovascular disease, diabetes, musculoskeletal disorders, sleep apnea and an increased risk of certain malignancies, such as breast, endometrial and colon cancer.^{6,7} It has been estimated that in young adults a BMI >45 reduces life expectancy by as much as 5 to 20 years.⁸

Obesity also has a profound impact on reproductive health. Women who have obesity are at increased risk for menstrual dysfunction, anovulatory infertility and pregnancy-related complications.⁹ In this guideline we will highlight the current literature related to obesity and reproduction, and present evidence-based recommendations using GRADE (Table 2).

WHAT IS THE IMPACT OF OBESITY ON FEMALE FERTILITY?

The impact of obesity on fecundity is complex.^{10,11} Perhaps the best understood association is that between obesity and anovulation. Obesity induces a hormonal milieu consisting of insulin resistance, hyperinsulinemia, low sex hormone-binding globulin, elevated androgens, increased peripheral conversion of androgens to estrogens, increased free insulin-like growth factor 1 and high leptin.^{12,13} The combined effect of these changes causes hypothalamic dysfunction, aberrant gonadotropin secretion, reduced folliculogenesis and lower luteal progesterone levels.^{14–16}

Table 2. GRADE

Recommendations are graded according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. GRADE offers two strengths of recommendation: strong and weak. The strength of the recommendation is based on the quality of supporting evidence, degree of uncertainty about the balance between desirable and undesirable effects, degree of uncertainty or variability in patient values and preferences and degree of uncertainty about whether the intervention represents a wise use of resources.
Strong recommendations are those for which the Canadian Task Force on Preventive Health Care is confident that the desirable effects of an intervention outweigh its undesirable effects (strong recommendation for an intervention) or that the undesirable effects of an intervention outweigh its desirable effects (strong recommendation against an intervention). A strong recommendation implies that most individuals will be best served by the recommended course of action.
Weak recommendations are those for which the desirable effects probably outweigh the undesirable effects (weak recommendation for an intervention) or undesirable effects probably outweigh the desirable effects (weak recommendation against an intervention), but appreciable uncertainty exists. Weak recommendations result when the balance between desirable and undesirable effects is small, the quality of evidence is lower, or there is more variability in the values and preferences of patients. A weak recommendation implies that most people would want the recommended course of action but that many would not. Clinicians must recognize that different choices will be appropriate for each individual, and they must help each person arrive at a management decision that is consistent with his or her values and preferences. Policy-making will require substantial debate and involvement of various stakeholders.
Quality of evidence is graded as high, moderate, low or very low, based on how likely further research is to change the task force's confidence in the estimate of effect.

As a result, menstrual irregularity is more common in women with obesity, and increases in frequency with the level of obesity.^{17,18} Several cohort studies have shown that the incidence of anovulatory infertility is more than twice as likely in women with obesity compared to normal BMI controls.^{19–21} Interestingly, the distribution of body fat is also important. It has been shown that women with higher waist circumference (excess abdominal fat) are more likely to suffer from anovulation than obese women with the same BMI who have less abdominal fat.^{22,23}

However, even in ovulatory women, obesity appears to inhibit natural fecundity and prolong the time to conception.^{18,24–27} A study of 3029 Dutch women with ovulatory cycles, at least one patent fallopian tube and whose partner had normal semen parameters revealed that the likelihood of pregnancy within a 12 month period was reduced by 4% for each kg/M² increase in BMI over 29.²⁸ In that study, women with a BMI of 35 had a 26% lower likelihood of spontaneous pregnancy, and women with a BMI of 40 had a 43% lower likelihood of spontaneous pregnancy than women with a BMI between 21 and 29. The authors commented that frequency of intercourse may be one potential cofounder. Obesity has been associated with decreased sexual desire, erectile dysfunction and decreased frequency of sexual intercourse.²⁹ However, a Danish study of 1651 women that controlled for frequency of sexual intercourse, cycle regularity and waist circumference confirmed a progressive increase in the time to pregnancy among both nulliparous and parous women as the BMI increased from 25 to 30 to over 35.³⁰

Obesity may also alter the endometrium.³¹ There is evidence of altered endometrial gene expression during the implantation window of natural cycles in obese women.³² Similarly, there is evidence of lower implantation and clinical pregnancy rates in obese donor egg recipients.^{33,34}

Recommendations

1. Women with obesity should be advised that their risk of anovulatory infertility is more than twice that of non-obese women (strong recommendation, moderate quality evidence).
2. Women with obesity should be advised that even when ovulatory, their natural fecundity rates are reduced (strong recommendation, moderate quality evidence).

WHAT IS THE IMPACT OF OBESITY ON MALE FERTILITY?

Obesity often affects both partners in a relationship.^{35,36} For men with obesity the average temperature of the scrotum

may be higher due to closer contact with surrounding tissues.^{37,38} Moreover, the combination of insulin resistance, reduced sex hormone binding globulin and increased peripheral conversion of androgens to estrogens may also disrupt gonadotropin release.^{39–41} Consequently, men with obesity have decreased testosterone levels, that correlate negatively with both their fasting insulin and leptin levels.^{42,43}

Despite these changes research regarding the relationship between male obesity and semen parameters has yielded conflicting results.⁴⁴ Some cohort studies have reported an association between male obesity and oligospermia,^{41,45–47} while others have found no such association.^{48–54} Likewise, meta-analyses have reported conflicting results with one reporting an increased risk of oligospermia and azoospermia,⁵⁵ while two others reported no impact of male obesity on semen parameters.^{56,57} Similarly, data regarding the impact of obesity on sperm DNA fragmentation has been mixed, with some studies suggesting a negative effect,^{57–59} while others report no differences.^{60–62} Thus, although it is clear that obese couples have a higher incidence of infertility,⁶³ it remains unclear to what extent changes in sperm quality contribute to this association.

In contrast the literature clearly shows that obese men have a higher incidence of erectile dysfunction.^{29,64,65} Several randomized controlled trials have demonstrated that lifestyle changes associated with weight loss may improve erectile dysfunction in obese men.^{66,67} Similarly, improvement in erectile function have been documented after bariatric surgery.^{68–72}

Recommendation

3. Men with obesity should be advised that they have increased risk of erectile dysfunction, and that this may be improved with weight loss (strong recommendation, high quality evidence).

WHAT IS THE IMPACT OF FEMALE OBESITY ON FERTILITY TREATMENTS?

Obesity has been associated with a reduced response to gonadotropins.^{73,74} In a large retrospective cohort study of 1189 gonadotropin/intrauterine insemination (IUI) cycles, BMI over 30 was associated with significantly higher gonadotropin requirements, prolonged gonadotropin stimulation, lower peak estradiol levels, and fewer large and medium size follicles.⁷⁵ The reduced responsiveness of obese women to gonadotropins is likely due to the increased volume of distribution. A randomized, crossover study showed that there was no difference in gonadotropin absorption between subcutaneous and intramuscular routes, but that a decline in area under the curve

Table 3. The impact of female obesity on IVF Outcomes

	BMI 18.5–24.9	BMI 25–29.9	BMI 30–34.9	BMI 35–39.9	BMI 40–44.9	BMI 45–49.9	BMI >50
Number of IVF cycles	134 588	54 822	24 922	11 747	4084	1292	463
Oocytes retrieved	12.4	12.3	12.3	12.1	11.6	11.2	10.5
Cancellation rate	10.3%	11.3%	11.3%	12.2%	13.3%	14.2%	11.7%
Embryos transferred	2.4	2.4	2.4	2.4	2.4	2.5	2.3
Implantation rate	29.5%	28.3%	26.9%	25.8%	23.6%	22.9%	20.3%
Clinical pregnancy rate	37.9%	36.8%	35.7%	33.7%	32%	30.6%	30%
Pregnancy loss rate	11.3%	12.7%	14.6%	15.3%	14.8%	17.6%	20.3%
Live birth rate	31.4%	29.8%	28%	26.3%	24.3%	22.8%	21.2%

Adapted from Provost et al.¹⁰¹

BMI: body mass index.

occurred in women with elevated BMI.⁷⁶ The same decline in area under the curve is true for injections of HCG, but in this case two separate cross-over studies have reported better serum levels if HCG is given intramuscularly compared to subcutaneously.^{77,78}

With regard to clinical pregnancy rates in women with obesity undergoing gonadotropin IUI study findings are mixed. Some studies report no difference^{73,74,79} in the clinical pregnancy rates in obese patients compared to non-obese controls, while several other report a paradoxical increase.^{75,80–82} Possible reasons for an increased effectiveness of gonadotropin/IUI in women with obesity include correction of anovulation, and compensation for erectile dysfunction and decreased frequency of intercourse.

In IVF patients, female obesity is associated with increased gonadotropin requirements (both increases starting dose and duration of gonadotropins), higher cycle cancellation rates, decreased peak estradiol levels and decreased oocyte yield.^{83–91} However, there has been little consensus regarding the impact of female obesity on IVF success rates. Some studies have reported reductions of clinical pregnancy and live birth rates on the order of 15% to 30% in obese women undergoing IVF compared to non-obese controls.^{83,85,86,90,92,93} Other studies have reported reductions in clinical pregnancy and live birth rates of more than 50%.^{94,95} In contrast, at least nine studies have reported no discernable impact of female obesity on IVF pregnancy rates.^{87–89,91,96–100}

The most comprehensive study to date regarding the impact of female obesity on IVF outcomes is from the Society for Assisted Reproductive Technology (SART) registry.¹⁰¹ This analysis involved 239 127 fresh IVF cycles from 2008 to 2010 and included over 6000 cycles in women with a BMI 30 to 40 and almost 1000 cycles in women with a BMI over 40.

The results of this study are summarized in Table 3. In brief, there is a slight decline in the number of oocytes retrieved and the number of high quality embryos as the BMI rises over 40. Implantation, clinical pregnancy and live birth rates all decline gradually with increasing severity of obesity. However, the absolute decline in pregnancy rates is small. Based on the data reported, implantation rates declined by approximately 0.2% to 0.25% and live birth rates declined by approximately 0.3% to 0.4% for each 1 kg/M² increase in BMI over 25. Thus the overall likelihood of a live birth per cycle start declined from 31.4% in women with a normal BMI, to 28% in women with BMI 30 to 34.9, to 24.3% in women with a BMI 40 to 44.5, and down to 21.2% in women with a BMI >50.

The exact mechanism by which obesity lowers IVF success rates is unclear. Some studies have demonstrated alterations in embryo development^{102,103} and day-3 spent culture media metabolomics¹⁰⁴ while others have not detected any changes of indicators of embryo quality between obese women and non-obese controls.^{90,105–107} Alternatively, obesity may alter endometrial receptivity.^{32,108}

Perhaps the best model to help elucidate the impact of obesity on reproduction is oocyte donation. Several studies have suggested that obesity does not impact donor egg recipient implantation or live birth rates^{109–111}; while other studies have found a negative association.^{112–114}

Again, the most comprehensive data comes from the SART registry.³⁴ In an analysis of 22 317 fresh donor/recipient cycles performed between 2008 and 2010 the implantation rate (49%) and live birth rate (51%) in normal BMI recipients declined to 41% in women with a BMI over 40. Moreover, the pregnancy loss rate before 24 weeks gestation increased from 8.6% in normal BMI recipients to 13.5% in recipients with a BMI over 40. This finding is

consistent with that of a meta-analysis of miscarriage risk after oocyte donation in obese recipients.¹¹⁵ Since the embryos came primarily from young, healthy donors there is no reason to suspect that the differences were related to an embryo factor. Indeed, an observational cohort study of 372 women with recurrent pregnancy loss showed that euploid miscarriages were significantly more common in women with obesity (58%) compared to non-obese controls (37%).¹¹⁶

This increase in pregnancy loss rate (8.6% with normal BMI to 13.5% with BMI over 40) in oocyte recipients is comparable to the change in pregnancy loss reported by SART in women using their own eggs: 11.3% with normal BMI to 14.8% with BMI 40 to 45, 17.6% with BMI 45–50 and 20.3% with BMI over 50¹⁰¹ suggesting that changes in embryo quality are probably not the primary driver for the BMI related increase in pregnancy loss rates after IVF. Obesity clearly increases miscarriage risk. However, the absolute risk of pregnancy loss in women with obesity undergoing IVF is still lower than the reported risk of spontaneous pregnancy loss in women with 2 or more prior pregnancy losses (25%) or women age over 40 ($\geq 35\%$).¹¹⁷

Aside from IVF outcomes, it is important to also recognize that obesity complicates the delivery of assisted reproductive technologies. In obese women undergoing controlled ovarian hyperstimulation, the ovaries may shift to a higher position in the pelvis, making them more difficult to visualize with transvaginal scanning and increasing the risk of complications with oocyte retrieval such as bleeding, infection, and injury to surrounding tissue. In addition, the risks of providing anesthesia to obese patients is well described, and makes management of these patients through non-hospital centres a challenge. In a recent survey of obesity policies at IVF facilities in the United States, 62% of respondents cited anesthesia concerns as the primary reason for their BMI cut-off.¹¹⁸

Recommendations

4. Women with severe obesity should be advised of a lower oocyte yield with IVF (strong recommendation, moderate quality evidence).
5. Women with an elevated BMI should be advised that implantation rates, clinical pregnancy rates and live birth rates decline with increasing severity of obesity. The best available evidence regarding live birth rates suggests a decline of approximately 0.3% to 0.4% for each 1 kg/M² increase in BMI over 25 (strong recommendation, moderate quality evidence).

6. Women with obesity should be advised that pregnancy loss rates prior to 24 weeks gestation increase as BMI increases (strong recommendation, moderate quality evidence).
7. Women with obesity using an egg donor should be advised that the live birth rate per cycle start is lower compared to non-obese recipients (strong recommendation, moderate quality evidence).
8. Women should be advised that obesity can compromise pelvic ultrasound imaging and the safety of oocyte retrieval (strong recommendation, low quality evidence).

WHAT IS THE IMPACT OF OBESITY ON MATERNAL RISKS OF PREGNANCY?

The risk of miscarriage is increased in women with obesity who conceive with IVF, irrespective of whether they use their own eggs or donor eggs. Miscarriage risks are also increased for women with obesity who conceive spontaneously. A recent Danish cohort study involving over 5000 women reported a hazard ratio for miscarriage of 1.23 in obese women compared to non-obese controls.¹¹⁹ Similar results were reported in a British population study involving 1644 women with obesity and 3288 controls (odds ratio 1.2 for miscarriage if obese).¹²⁰ Among women with recurrent miscarriages the association with obesity may be even greater. Two studies have suggested that among women with recurrent miscarriages the odds of the next pregnancy resulting in miscarriage is elevated 3- to 4-fold in obese patients.^{120,121}

Women with obesity who conceive are also at greater risk for gestational diabetes. The baseline risk of gestational diabetes in over one million pregnancies in Ontario from 1996 to 2010 was documented as 4.1%.¹²² Similarly, a study of over 400 000 pregnancies in Alberta found that the incidence of gestational diabetes increased from 3.1% in 2000 to 4.6% in 2009.¹²³ In British Columbia, a study of 226 000 singleton pregnancies from 2004 to 2012 reported the incidence of gestational diabetes as 7.9%.¹²⁴ In that study the risk of gestational diabetes increased steadily with increasing BMI (Table 4). The risk of gestational diabetes was doubled with a BMI over 30 and more than tripled with a BMI over 40.

The risk of preeclampsia is doubled in women that are overweight, and tripled in those that are obese.^{124,125} The risk further increases with the severity of obesity (Table 4). It has been suggested that increasing physical activity in pregnancy may reduce the incidence of both gestational diabetes and pre-eclampsia.¹²⁶ However, a recent multicentre randomized control trial in over 1500 women with obesity found no difference in the incidence of gestational diabetes or mac-

Table 4. Risk of adverse maternal and perinatal outcomes with increasing BMI in a population cohort study of over 226 000 pregnancies in British Columbia

	BMI 18.5–24.9 n = 144 502	BMI 25–29.9 n = 46 317	BMI 30–34.9 n = 17 210	BMI 35–39.9 n = 6695	BMI ≥40 n = 3380	P value
Gestational diabetes	6.1%	9.7%	13.7%	16.6%	20.8%	<0.001
Preeclampsia	3.4%	6.4%	10%	12.8%	16.3%	<0.001
Macrosomia	1.4%	2.8%	3.8%	4.5%	6.1%	<0.001
Shoulder dystocia	3.5%	4.1%	4.1%	4.4%	4.1%	<0.001
Birth injury from shoulder dystocia	0.1%	0.1%	0.1%	0.2%	0.3%	<0.001
Cesarean delivery	26.5%	33.1%	38.2%	43.1%	49.7%	<0.001
Indicated birth <37 weeks	1.6%	2%	2.5%	3.4%	4.1%	<0.001
Stillbirth	0.3%	0.3%	0.4%	0.4%	0.6%	<0.001
Birth <32 weeks	0.6%	0.6%	0.6%	0.6%	0.5%	NS
Maternal mortality	0.6%	0.6%	0.6%	0.5%	0.6%	NS

Adapted from Schummers et al.¹²⁴

BMI: body mass index.

rosomia in women randomized to behavioural intervention in pregnancy, versus routine care.¹²⁷

A recent Canadian meta-analysis revealed that there is a 31% increased risk of delivery prior to 37 weeks in obese women.^{125,128} This may be related to the higher incidence of preterm premature rupture of membranes (PPROM) and need for medical induction of labour. PPRM might be more common in obese patients with increased circulating adipokines and inflammatory proteins. Increased rates of sleep apnea and antenatal depression have also been reported.^{125,128}

A systematic review of the risks associated with obesity in pregnancy demonstrated that pregnant women with obesity have a longer duration of labour, particularly the first stage (4.7 hours compared with 4.1 hours in non-obese women).^{129–131} Women who with obesity have less successful trials of labour and vaginal birth after Caesarean section (VBAC): 54% to 68% success if BMI >29, 13% if weight >136 kg/300 lbs. There is increased fetal distress, instrumental delivery, and shoulder dystocia in women with obesity going through labour (Table 4).^{125,128} The Caesarean section rate increases significantly with increasing BMI (Table 4).^{125,132–133} There are also increases in wound infection and dehiscence, post-partum hemorrhage and DVT.^{125,132,134}

Recommendations

9. Women with obesity should be advised that they have increased prenatal risk of having gestational diabetes and preeclampsia (strong recommendation, moderate quality evidence).

10. Women with obesity should be advised of increased peri-partum risks such as a prolonged first stage of labour, less success with VBAC, increased instrumental deliveries, shoulder dystocia and cesarean section rates (strong recommendation, moderate quality evidence).
11. Women with obesity should be aware that these obstetrical risks are increased with higher BMI (strong recommendation, moderate quality evidence).

WHAT IS THE IMPACT OF OBESITY ON FETAL/NEONATAL RISKS OF PREGNANCY?

Women with obesity are also at an increased risk of fetal macrosomia (Table 4), an association compounded by the presence of gestational diabetes. A recent Swedish population-based cohort study involving 1 249 908 singleton births between 1998 and 2012 documented an incidence of macrosomia of 7.7% for non-obese women without gestational diabetes, compared to 14% in gestational diabetics.¹³⁵ The odds ratio for macrosomia in women with obesity was 2.55 (95% CI 2.51–2.59) without gestational diabetes compared to 6.50 (95% CI 6.10–6.92) with. Macrosomia increases the need for obstetrical interventions like induction of labour and Caesarean section, and increases the incidence of a number of complications such as shoulder dystocia, nerve palsy, and NICU admission. Maternal obesity also increases the risk of obesity in the child, with a higher risk of diabetes and cardiovascular disease later in life.^{135–139}

The National Birth Defect Prevention Study found that the mothers of offspring with anomalies were more likely

to have obesity, with an odds ratio of 1.3 to 2.1, suggesting that maternal adiposity alters development in the embryonic period.¹⁴⁰ In the 10 249 cases compared to the 4065 controls, there was a 39% increase in neural tube defects,¹⁴¹ with 50% increase in spina bifida, and 20% increase in oral clefts. Hydrocephaly (OR 1.68), anorectal atresia (OR 1.48), limb reduction anomalies (OR 1.34) and cardiovascular anomalies were also increased. The metabolic basis for those anomalies is not known, but poor glycemic control may play a role. Some have advocated for increased folic acid supplementation but evidence to support this practice is unclear.¹⁴² Obesity can also prevent visualization of congenital defects on ultrasound possibly leading to their discovery later in pregnancy or lack of prenatal detection. A large retrospective study demonstrated 20% less detection of anomalous fetuses in women with high BMI compared to normal BMI.¹⁴³

Recommendation

12. Women with obesity should be advised that their risk of having a baby with macrosomia or a congenital anomaly is increased (strong recommendation, moderate quality evidence).

WHAT SCREENING TESTS ARE APPROPRIATE FOR WOMEN WITH OBESITY SEEKING FERTILITY CARE?

The 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children contain recommendations for assessment of obesity and its complications.¹⁴⁴ Obesity induces insulin resistance and a baseline inflammatory state and increases the risk of diabetes, hypertension, dyslipidemia and cardiovascular disease.^{145–149} The prevalence of diabetes in the United States general population increases with BMI (8% risk if normal BMI, 43% risk if BMI ≥ 40 kg/m²) and obesity is the most important modifiable risk factor for the prevention of type 2 diabetes.^{150,151} An analysis of the United States National Health and Nutrition Examination Survey (NHANES) found the prevalence of diabetes in 2011–2012 among adults aged 22 to 44 years was 5.0% (95% CI 3.8–6.7), and when stratified by BMI, the increase in prevalence of diabetes from 1988 to 2012 was seen only among those with BMI ≥ 30 , regardless of age.¹⁵² NHANES also found that regardless of age, ethnicity, education or smoking habits, lipid profile worsened and the risk of hypertension increased with increasing BMI.¹⁵³ In this study, woman age 20–39 with a BMI ≥ 30 were 7 times more likely to have high blood pressure, 3.4 times more likely to have high cholesterol, and 13.2 times more likely to have low HDL cholesterol than women with a BMI < 25 . Not surprisingly obesity, and particularly

central obesity, is associated with increased risk of cardiovascular disease.^{153–155}

Abundant literature demonstrates that elevated BMI is associated with an increased risk for complex endometrial hyperplasia and endometrial cancer in premenopausal women.^{156–160} In a recent review the pooled odds ratio for endometrial cancer was 5.3 in women with a BMI > 30 and 19.8 in women with a BMI > 40 .³¹ Similarly, a prospective cohort study followed 495 477 women in the United States for 16 years showed a significant increase in risk of mortality from cancers according to BMI.⁷ Compared to non-obese controls, women with a BMI of 40 or more had a relative risk of 2.1 for dying from breast cancer and a relative risk of 6.3 of dying from endometrial cancer.

Women with obesity are also at risk for obstructive sleep apnea: periodic, partial or complete obstruction of the upper airway during sleep which leads to repetitive arousal from sleep.¹⁶¹ The airway obstruction may also cause episodic sleep-associated oxygen desaturation, episodic hypercapnia, significant negative intrathoracic pressure and cardiovascular dysfunction.¹⁶² Approximately 35% of women with a BMI ≥ 35 report symptoms compatible with obstructive sleep apnea.^{163,164} Sleep apnea exacerbates the cardio-metabolic risk attributed to obesity and metabolic syndrome.¹⁶⁵ Self-reported sleep apnea appears to be an independent prognostic marker of all-cause mortality.¹⁶⁶

Recommendations

13. Women with obesity should be informed that they are at increased risk of metabolic abnormalities (diabetes, dyslipidemia, hypertension), cardiovascular disease, breast and endometrial cancer (strong recommendation, moderate quality evidence).
14. Prior to starting fertility treatment, women with obesity should be advised to have screening for and appropriate management of comorbidities such as diabetes, hypertension and dyslipidemia (strong recommendation, moderate quality evidence).

WHAT ARE THE MOST EFFECTIVE TREATMENTS TO HELP INFERTILE WOMEN WITH OBESITY LOSE WEIGHT?

Canadian guidelines on managing obesity have focused primarily on eating habits and exercise.¹⁶⁷ The 2015 Canadian Task Force on Preventive Health Care recommended structural behavioural interventions focused on diet and exercise as first-line treatment for patients with a BMI 30 to 39.9.¹ Pharmacotherapy and surgery are options for more severe cases of obesity (BMI ≥ 40). It should be noted that body

weight is tightly regulated by a complex homeostatic system and that powerful neuroendocrine mechanisms defend the body against weight loss, thus accounting for the over 95% recidivism (weight regain) generally associated with behavioural obesity management.^{168,169} The same is seen when pharmacologic treatments are discontinued or bariatric surgery is reversed.

LIFESTYLE MODIFICATION

Obesity has been associated with poor body image, low self-esteem, depression and anxiety, all of which may influence binge eating.^{170,171} One of the challenges of lifestyle modification is breaking this pattern and introducing behavioural strategies that facilitate weight loss and prevent weight regain.¹⁷²

Lifestyle modification with diet and exercise yields modest weight loss. Dietary interventions typically focus on reduced energy uptake from fat and carbohydrates, and increased uptake of fruits, vegetables, whole grains and nuts. The Diabetes Prevention Program (DPP, 3234 participants)^{173,174} and Diabetes Prevention Study (DPS, 522 participants)¹⁷⁵ showed that weight loss of approximately 4 to 6 kg could be achieved following an intensive program of lifestyle changes (counselling, education, support, changes in exercise and diet) and that this was sufficient to reduce the incidence of type 2 diabetes, metabolic syndrome and dyslipidemia in individuals at risk. Unfortunately, weight lost in the first year of lifestyle intervention is gradually gained back, and in the DPP study, total weight loss in the intervention group was 2 kg after 10 years, which was only 1 kg more than in the control group.¹⁷⁶ Indeed, the meta-analysis on which the current Canadian weight loss guidelines are based noted an average weight loss of only 3.1 kg (95% CI 2.4–3.9) with behavioural interventions.¹⁷⁷

PHARMACOTHERAPY

Current Canadian guidelines recommend adding pharmacological treatment only when lifestyle modification is not sufficient to achieve or maintain clinically significant weight loss.¹ The rationale for this approach is that behavioural modification has better benefit-to-harm ratio than pharmacotherapy. In Canada, two drugs are currently approved by Health Canada for the treatment of obesity—Orlistat and Liraglutide. Orlistat (Xenical®) is a selective absorption fat inhibitor.^{178–180} It exerts an effect in the digestive tract by binding to gastric and pancreatic lipases and prevents absorption of at least 30% of dietary fat. However, side effects include flatulence, greasy stool, fecal urgency and abdominal cramps. Liraglutide (Saxenda®) is an analogue of human glucagon-like-peptide-1.^{181,182} Liraglutide leads to

weight loss by decreasing appetite. The most common side effects are nausea, diarrhea and hypoglycaemia by stimulating insulin secretion and inhibiting glucagon. Liraglutide 1.2 to 3 mg subcutaneously per day may lead to greater weight loss (4.8–7.2 kg after 20 weeks) than Orlistat 120 mg by mouth 3 times per day (4.1 kg after 20 weeks).¹⁸¹ The safety of both of these drugs in pregnancy is unknown. Although metformin is not specifically approved by Health Canada for weight loss, its properties in this regard have been well studied.^{1,183–190} Current data suggests that metformin induces weight loss of an average of 1.9 kg, while Orlistat on average 3.1 kg.¹⁷⁷ Unfortunately, even in controlled trials with fixed timelines, drop-out rates with weight loss medications typically exceed 30%.¹⁹¹

BARIATRIC SURGERY

Bariatric surgery is considered when the BMI is over 40, or if BMI exceeds 35 with comorbidities, and if other weight loss attempts have failed.¹⁶⁷ Bariatric surgery modifies the architecture of the digestive tract in order to limit caloric intake. There are restrictive procedures such as vertical banded gastroplasty, laparoscopic adjustable gastric banding or sleeve gastrectomy designed to accelerate the feeling of “being full,” and there are malabsorptive procedures such as biliopancreatic diversion with or without duodenal switch that are designed to reduce nutrient absorption. Bariatric surgery may also be a mixed restrictive/malabsorptive procedure as Roux en Y gastric bypass. In malabsorptive or mixed procedures, the greater the excluded intestinal portion, the greater the decrease in caloric intake.^{192,193}

Bariatric surgery typically induces significant weight loss. The Swedish Obese Subjects (SOS) study included over 2000 bariatric surgery patients and showed that maximal weight loss was achieved after 1 year (gastric bypass 45 kg, vertical banded gastroplasty 30.8 kg and gastric banding 24.9 kg) but that significant weight reduction was maintained even after 10 years of follow-up (gastric bypass 29.6 kg, vertical banded gastroplasty 19.5 kg and gastric banding 15.6 kg).¹⁹⁴ Other studies have confirmed profound weight loss 1 to 2 years after gastric bypass surgery (29–45 kg), biliopancreatic diversion (48 kg) and sleeve-gastrectomy (25.1 kg).^{195,196}

Furthermore, bariatric surgery improves metabolic profile and significantly reduces all-cause mortality.^{164,197} In fact, bariatric surgery has been shown to be more effective than usual care in the prevention of type 2 diabetes,¹⁹⁸ and more effective than medical therapy in the treatment of type 2 diabetes in obese patients.¹⁹⁶ Finally, among obese patients with uncontrolled type 2 diabetes, three years of intensive medical therapy plus bariatric surgery results in

significantly better glycemic control and weight reduction than medical therapy alone.¹⁹⁵

Mortality associated with bariatric surgery is less than 1%.¹⁹⁹ The most common postoperative complications in the SOS study were pulmonary complications (6.1%). Other complications (<5%) are bleeding, venous thrombosis, wound infections, anastomotic leaks.¹⁶⁴ Long term complications include vitamin deficiencies in 20% to 50% of cases. Surgical complications (internal bowel herniation) related to the previous bariatric procedure may also impact 1% of pregnancies.²⁰⁰ Depending on the procedure, complications may lead to health problems: anemia (iron, B12 and folate deficiencies), osteopenia (loss in calcium and vitamin D), alopecia (zinc deficiency), muscle weakness (magnesium deficiency), visual disorders, neuropathy, and hemorrhagic disease (Vitamins A, C, E and K deficiencies).^{201,202} For these reasons bariatric surgery requires long-term monitoring.

DELAY OF CONCEPTION AFTER BARIATRIC SURGERY

There are no prospective randomized trials addressing time to conception after bariatric surgery. Nevertheless, concerns over the impact of rapid weight loss and vitamins deficiencies on the mother and fetus, delaying pregnancy for one to two years after bariatric surgery has been recommended.^{203–205} A retrospective study comparing 104 pregnancies conceived less than one year after bariatric surgery to 385 pregnancies conceived more than year after bariatric surgery found no differences between the two groups regarding bariatric complications, pregnancy related complications or perinatal outcomes.²⁰⁶ Similarly, a Danish cohort study involving 158 women who conceived within the first year of Roux en Y gastric bypass surgery to 128 women who conceived after one year found no difference obstetric or neonatal outcomes between the two groups.²⁰⁷ Thus, particularly in the late reproductive years, the possible benefits of postponing pregnancy must be balanced against the risk of declining reproductive potential with advancing age.

ADVERSE OBSTETRIC AND NEONATAL OUTCOMES AFTER BARIATRIC SURGERY

Bariatric surgery significantly reduces the risk of gestational diabetes, fetal macrosomia and hypertensive disorders of pregnancy.^{208–211} Unfortunately, bariatric surgery also increases the risk of maternal anemia²¹² and the risk of small-for-gestational age (SGA) infants.^{210,213,214} In nationwide Danish registry-based cohort study obese women who con-

ceived following bariatric surgery were 3.3 times less likely to have a large-for-gestational age (LGA) infant but 2.3 times more likely to have a SGA infant compared to BMI matched controls.²¹⁴ Similarly, a nationwide Swedish registry-based cohort study that matched 670 pregnancies in women who had previously undergone bariatric surgery to five controls matched for pre-surgery BMI reported reduced risks for gestational diabetes (1.9% vs. 6.8%) and LGA infants (8.6% vs. 22.4%) but a higher risk for SGA infants (15.6% vs. 7.6%).²¹⁰ In that study, the median time from surgery to conception was 1.1 years and, of concern, the risk of still birth or neonatal death (1.7% vs. 0.7%; OR 2.39; 95% CI 0.98–5.85; $P=0.06$) was slightly higher in the bariatric surgery group.

To date there does not appear to be a difference in obstetric or neonatal outcomes based on the type of bariatric surgery performed. A study that compared laparoscopic gastric banding, ring vertical gastropasty and vertical banded gastropasty reported no significant differences in subsequent obstetric or perinatal outcomes between the three procedures.²¹⁵ Similarly, another study reported comparable neonatal outcomes between women conceiving after laparoscopic adjustable gastric banding and Roux en Y gastric bypass.²¹⁶

Recommendations

15. Women with obesity should be advised that modest reductions in weight combined with lifestyle modification will improve their metabolic profile (strong recommendation, moderate quality evidence).
16. Women with obesity should be offered or referred for lifestyle modifications (diet + exercise) as a first-line effort to help them lose weight (strong recommendation, low quality evidence).
17. Women with obesity who fail to lose weight with lifestyle modification may be offered a referral to other practitioners/specialists who can appropriately counsel them regarding alternative therapies such as pharmacotherapy and bariatric surgery (strong recommendation, moderate quality evidence).
18. Women who have undergone bariatric surgery should be advised that the possible benefits of waiting for 1–2 years after surgery before attempting conception should be balanced against the decline in fertility related to advancing age (strong recommendation, low quality evidence).
19. Women who have undergone bariatric surgery should be advised that they are at lower risk for fetal macrosomia, gestational diabetes and hypertension, but at higher risk for small-for-gestational age infants (strong recommendation, good quality evidence).

IS THERE DATA DEMONSTRATING A DIFFERENCE IN OUTCOMES FOR WOMEN WITH OBESITY WHO LOSE WEIGHT COMPARED TO WOMEN WITH OBESITY WHO PROCEED DIRECTLY TO TREATMENT?

In anovulatory women with obesity, weight loss of 5% to 10% can induce ovulation and increase the chance of pregnancy.^{217–221} One weight loss intervention study randomized 49 women to either an intensive 12-week dietary intervention (n = 27) or simply written instructions on how to lose weight (n = 22).²²² The 22 women who completed the intensive intervention lost an average of 6.6 kg while the controls lost an average of 1.6 kg. Despite just a 5 kg difference in weight loss the authors reported significantly more pregnancies (48% vs. 14%; $P = 0.007$) and live births (44% vs. 14%) in the intervention group. Similarly, striking results (live birth rates of 71% vs. 37%; n = 52) have been reported for women with a BMI >25 who succeed in achieving meaningful weight loss ($\geq 10\%$ of their weight).²²³

Following bariatric surgery, it has been estimated that 58% of previously infertile women with obesity may conceive spontaneously.²²⁴ Bariatric surgery may also increase the number and quality of oocytes obtained at the time of IVF treatment²²⁵; however, it is unclear if this increase actually improves clinical outcomes.²²⁶

Recommendation

20. Women with obesity should be advised that weight loss improves spontaneous fecundity rates (strong recommendation, low quality evidence).

SHOULD THERE BE A NATIONAL BMI CUT-OFF FOR ACCESS TO FERTILITY CARE?

Concerns regarding poor clinical outcomes and maternal/fetal risks have led to calls to restrict access to fertility treatments in women with elevated BMI.^{227,228} A 2014 survey of Canadian IVF medical directors found that 50% of respondents imposed a BMI cut-off.²²⁹ The median upper permitted BMI was 38 and the interquartile range was between 35 and 40. The National Institute of Clinical Excellence (NICE) guideline states that it is desirable to achieve a BMI below 30 prior to commencing fertility treatment.²³⁰ In 2000, clinical priority criteria in New Zealand restricted women with a BMI >32 from accessing fertility treatment.²³¹ In 2007, the British Fertility Society recommended deferring fertility treatment until a woman's BMI was below 35,²³² and most IVF units in the United Kingdom impose BMI cut-offs between 30 and 35.²³³

Thus far the American Society for Reproductive Medicine has resisted calling for a national BMI cut-off.⁴⁰ However, many providers believe that BMI cut-offs should exist.²³⁴ In a 2014 survey of 349 clinics, 35% (n = 120) reported using a BMI or body weight cut-off to determine IVF eligibility.²³⁵ In that study the mean BMI cut-off was 38.4 and the mean weight cut-off was 130 kg. Among the clinics with a BMI cut-off, only 54% provided weight loss instructions for their patients. Another survey that involved 77 responding clinics reported that 65% had a BMI cut-off (50% between 35–40, 24% between 40–45).¹¹⁷ Most cited anesthesia requirements as the primary reason for having a cut-off, and only 38% of respondents had a BMI cut-off for intrauterine insemination.

Clearly, there is no consensus in clinical practice. Furthermore, we must recognize that any specific cut-off value is arbitrary, and that for many patients, weight loss is difficult to achieve. Most weight loss interventions result in less than 7 kg of weight reduction. For a woman of average height (163.5 cm) this results in 3 kg/M² or less change in BMI. Although it might improve their metabolic profile, it is unclear that this amount of weight reduction substantially changes the maternal/fetal risks of pregnancy.

The situation is further complicated by the increasing number of women who are obese. From an ethics perspective, clinician's duty to respect their patients' decision-making autonomy is counterbalanced by their duty to do no harm. This duty extends not only to the patient with obesity, who may suffer irreversible health complications as a consequence of pregnancy, but also to the child-not-yet-born whose health may be significantly compromised as a consequence of the mother's obesity. Clearly, weight loss should be encouraged. However, the risk, benefits and limitations of weight loss interventions prior to fertility treatment should be balanced against the risks, benefits and limitations of proceeding directly to fertility treatments.

It is important to recognize that denying fertility care leads to stigmatization, may be perceived as discriminatory; and can exacerbate feelings of low self-esteem, social isolation, anxiety and depression.^{236–238} Moreover, denying fertility treatment to older obese women or women with diminished ovarian reserve until they have lost a specific amount of weight may cost them valuable time and any chance of pregnancy.²³⁹

In other areas of healthcare, the risk of complications does not necessarily prevent obese patients from receiving elective medical care. Although obese women face a higher chance of obstetric complications their absolute risks remain low. Moreover, their risk of complications does not clearly

exceed the risk of complications encountered with other pre-existing medical conditions such as diabetes, hypertension and epilepsy. Thus, in the absence of simple, safe effective strategies that reliably help patients with obesity lose weight in a timely fashion, it is difficult to advocate for a universal BMI cut-off in place of careful counselling, screening for metabolic abnormalities and informed consent.

Recommendation

21. Programs that impose BMI cut-offs should offer resources for patients to help them lose weight and should inform patients about both the risks and benefits of delaying fertility treatment (strong recommendation, low quality evidence).

CONCLUSION

The prevalence of obesity is steadily increasing and affects a substantial number of reproductive age women in Canada. Obesity reduces natural fertility rates and those from fertility treatments. Women with obesity have a reduced response to fertility medications, reduced likelihood of success with assisted reproductive technologies, increased risk of miscarriage and increased risk of maternal/fetal complications in pregnancy. Weight loss is the mainstay of treatment and is important for optimizing the safety and success of natural and treatment-related conception. Unfortunately, it is not easy for patients with obesity to lose weight and, aside from bariatric surgery, most interventions result in only modest weight reductions that are difficult to maintain. Therefore, patients with obesity should be assessed carefully in the preconception period and comorbid conditions addressed. A careful balance should then be sought between the principle to do no harm and the responsibility to respect patient autonomy.

REFERENCES

- Brauer P, Connor Gorber S, Shaw E, et al. Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care. *CMAJ* 2015;187:184–95.
- Vandevijvere S, Chow CC, Hall KD, et al. Increased food energy supply as a major driver of the obesity epidemic: a global analysis. *Bull World Health Organ* 2015;93:446–56.
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser* 2000;894:i–xii, 1–253.
- Lee CM, Huxley RR, Wildman RP, et al. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. *J Clin Epidemiol* 2008;61:646–53.
- Paterson N, Sharma AM, Maxwell C, et al. Obesity-related health status is a better predictor of pregnancy with fertility treatment than body mass index: a prospective study. *Clin Obes* 2016;6:243–8.
- Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. *BMJ* 2016;353:i2156.
- Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003;348:1625–38.
- Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. *JAMA* 2003;289:187–93.
- Ramsay JE, Greer I, Sattar N. ABC of obesity. Obesity and reproduction. *BMJ* 2006;333:1159–62.
- Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. *Reproduction* 2010;140:347–64.
- Pantastri T, Norman RJ. The effects of being overweight and obese on female reproduction: a review. *Gynecol Endocrinol* 2014;30:90–4.
- Norman JE. The adverse effects of obesity on reproduction. *Reproduction* 2010;140:343–5.
- Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. *BJOG* 2006;113:1148–59.
- Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. *Reprod Biomed Online* 2006;12:542–51.
- Pasquali R, Pelusi C, Genghini S, et al. Obesity and reproductive disorders in women. *Hum Reprod Update* 2003;9:359–72.
- Jain A, Polotsky AJ, Rochester D, et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. *J Clin Endocrinol Metab* 2007;92:2468–73.
- Castillo-Martinez L, Lopez-Alvarenga JC, Villa AR, et al. Menstrual cycle length disorders in 18- to 40-y-old obese women. *Nutrition* 2003;19:317–20.
- Polotsky AJ, Hailpern SM, Skurnick JH, et al. Association of adolescent obesity and lifetime nulliparity—the Study of Women’s Health Across the Nation (SWAN). *Fertil Steril* 2010;93:2004–11.
- Rich-Edwards JW, Goldman MB, Willett WC, et al. Adolescent body mass index and infertility caused by ovulatory disorder. *Am J Obstet Gynecol* 1994;171:171–7.
- Grodstein F, Goldman MB, Cramer DW. Body mass index and ovulatory infertility. *Epidemiology* 1994;5:247–50.
- Jacobsen BK, Knutsen SF, Oda K, et al. Obesity at age 20 and the risk of miscarriages, irregular periods and reported problems of becoming pregnant: the Adventist Health Study-2. *Eur J Epidemiol* 2012;27:923–31.
- Kuchenbecker WK, Groen H, Zijlstra TM, et al. The subcutaneous abdominal fat and not the intraabdominal fat compartment is associated with anovulation in women with obesity and infertility. *J Clin Endocrinol Metab* 2010;95:2107–12.
- Moran C, Hernandez E, Ruiz JE, et al. Upper body obesity and hyperinsulinemia are associated with anovulation. *Gynecol Obstet Invest* 1999;47:1–5.
- Gesink Law DC, Maclehorse RF, Longnecker MP. Obesity and time to pregnancy. *Hum Reprod* 2007;22:414–20.

25. Jensen TK, Scheike T, Keiding N, et al. Fecundability in relation to body mass and menstrual cycle patterns. *Epidemiology* 1999;10:422–8.
26. Zaadstra BM, Seidell JC, Van Noord PA, et al. Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. *BMJ* 1993;306:484–7.
27. Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical activity, body mass index, and ovulatory disorder infertility. *Epidemiology* 2002;13:184–90.
28. van der Steeg JW, Steures P, Eijkemans MJ, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. *Hum Reprod* 2008;23:324–8.
29. Kolotkin RL, Zunker C, Ostbye T. Sexual functioning and obesity: a review. *Obesity (Silver Spring)* 2012;20:2325–33.
30. Wise LA, Rothman KJ, Mikkelsen EM, et al. An internet-based prospective study of body size and time-to-pregnancy. *Hum Reprod* 2010;25:253–64.
31. Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. *Am J Obstet Gynecol* 2016.
32. Bellver J, Martinez-Conejero JA, Labarta E, et al. Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. *Fertil Steril* 2011;95:2335–41, 41.e1–8.
33. Dessolle L, Darai E, Cornet D, et al. Determinants of pregnancy rate in the donor oocyte model: a multivariate analysis of 450 frozen-thawed embryo transfers. *Hum Reprod* 2009;24:3082–9.
34. Provost MP, Acharya KS, Acharya CR, et al. Pregnancy outcomes decline with increasing recipient body mass index: an analysis of 22,317 fresh donor/recipient cycles from the 2008–2010 Society for Assisted Reproductive Technology Clinic Outcome Reporting System registry. *Fertil Steril* 2016;105:364–8.
35. Cobb LK, McAdams-DeMarco MA, Gudzone KA, et al. Changes in body mass index and obesity risk in married couples over 25 years: the ARIC cohort study. *Am J Epidemiol* 2016;183:435–43.
36. Chen HJ, Liu Y, Wang Y. Socioeconomic and demographic factors for spousal resemblance in obesity status and habitual physical activity in the United States. *J Obes* 2014;2014:703215.
37. Palmer NO, Bakos HW, Fullston T, et al. Impact of obesity on male fertility, sperm function and molecular composition. *Spermatogenesis* 2012;2:253–63.
38. Jo J, Kim H. The relationship between body mass index and scrotal temperature among male partners of subfertile couples. *J Therm Biol* 2016;56:55–8.
39. Pasquali R. Obesity and androgens: facts and perspectives. *Fertil Steril* 2006;85:1319–40.
40. Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. *Fertil Steril* 2015;104:1116–26.
41. Jensen TK, Andersson AM, Jorgensen N, et al. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. *Fertil Steril* 2004;82:863–70.
42. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. *J Clin Endocrinol Metab* 2005;90:2636–41.
43. Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. *J Clin Endocrinol Metab* 1999;84:3673–80.
44. Du Plessis SS, Cabler S, McAlister DA, et al. The effect of obesity on sperm disorders and male infertility. *Nat Rev Urol* 2010;7:153–61.
45. Hammoud AO, Wilde N, Gibson M, et al. Male obesity and alteration in sperm parameters. *Fertil Steril* 2008;90:2222–5.
46. Wang EY, Huang Y, Du QY, et al. Body mass index effects sperm quality: a retrospective study in Northern China. *Asian J Androl* 2016.
47. Hakonsen LB, Thulstrup AM, Aggerholm AS, et al. Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men. *Reprod Health* 2011;3:24.
48. Aggerholm AS, Thulstrup AM, Toft G, et al. Is overweight a risk factor for reduced semen quality and altered serum sex hormone profile? *Fertil Steril* 2008;90:619–26.
49. Li Y, Lin H, Ma M, et al. Semen quality of 1346 healthy men, results from the Chongqing area of southwest China. *Hum Reprod* 2009;24:459–69.
50. Chavarro JE, Toth TL, Wright DL, et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. *Fertil Steril* 2010;93:2222–31.
51. Duits FH, van Wely M, van der Veen F, et al. Healthy overweight male partners of subfertile couples should not worry about their semen quality. *Fertil Steril* 2010;94:1356–9.
52. Martini AC, Tissera A, Estofan D, et al. Overweight and seminal quality: a study of 794 patients. *Fertil Steril* 2010;94:1739–43.
53. Eskandar M, Al-Asmari M, Babu Chaduvula S, et al. Impact of male obesity on semen quality and serum sex hormones. *Adv Urol* 2012;2012:407601.
54. Macdonald AA, Stewart AW, Farquhar CM. Body mass index in relation to semen quality and reproductive hormones in New Zealand men: a cross-sectional study in fertility clinics. *Hum Reprod* 2013;28:3178–87.
55. Sermondade N, Faure C, Fezeu L, et al. BMI in relation to sperm count: an updated systematic review and collaborative meta-analysis. *Hum Reprod Update* 2013;19:221–31.
56. MacDonald AA, Herbison GP, Showell M, et al. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. *Hum Reprod Update* 2010;16:293–311.
57. Campbell JM, Lane M, Owens JA, et al. Paternal obesity negatively affects male fertility and assisted reproduction outcomes: a systematic review and meta-analysis. *Reprod Biomed Online* 2015;31:593–604.
58. Dupont C, Faure C, Sermondade N, et al. Obesity leads to higher risk of sperm DNA damage in infertile patients. *Asian J Androl* 2013;15:622–5.
59. Fariello RM, Pariz JR, Spaine DM, et al. Association between obesity and alteration of sperm DNA integrity and mitochondrial activity. *BJU Int* 2012;110:863–7.
60. Bandel I, Bungum M, Richtoff J, et al. No association between body mass index and sperm DNA integrity. *Hum Reprod* 2015;30:1704–13.
61. Eisenberg ML, Kim S, Chen Z, et al. The relationship between male BMI and waist circumference on semen quality: data from the LIFE study. *Hum Reprod* 2014;29:193–200.

62. Rybar R, Kopecka V, Prinosilova P, et al. Male obesity and age in relationship to semen parameters and sperm chromatin integrity. *Andrologia* 2011;43:286–91.
63. Ramlau-Hansen CH, Thulstrup AM, Nohr EA, et al. Subfecundity in overweight and obese couples. *Hum Reprod* 2007;22:1634–7.
64. Pasquali R. Obesity, fat distribution and infertility. *Maturitas* 2006;54:363–71.
65. Han TS, Tajar A, O'Neill TW, et al. Impaired quality of life and sexual function in overweight and obese men: the European Male Ageing Study. *Eur J Endocrinol* 2011;164:1003–11.
66. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. *JAMA* 2004;291:2978–84.
67. Collins CE, Jensen ME, Young MD, et al. Improvement in erectile function following weight loss in obese men: the SHED-IT randomized controlled trial. *Obes Res Clin Pract* 2013;7:e450–4.
68. Kun L, Pin Z, Jianzhong D, et al. Significant improvement of erectile function after Roux-en-Y gastric bypass surgery in obese Chinese men with erectile dysfunction. *Obes Surg* 2015;25:838–44.
69. Groutz A, Gordon D, Schachter P, et al. Effects of bariatric surgery on male lower urinary tract symptoms and sexual function. *NeuroUrol Urodyn* 2016.
70. Efthymiou V, Hyphantis T, Karaivazoglou K, et al. The effect of bariatric surgery on patient HRQOL and sexual health during a 1-year postoperative period. *Obes Surg* 2015;25:310–8.
71. Mora M, Aranda GB, de Hollanda A, et al. Weight loss is a major contributor to improved sexual function after bariatric surgery. *Surg Endosc* 2013;27:3197–204.
72. Reis LO, Favaro WJ, Barreiro GC, et al. Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. *Int J Androl* 2010;33:736–44.
73. Dodson WC, Kunselman AR, Legro RS. Association of obesity with treatment outcomes in ovulatory infertile women undergoing superovulation and intrauterine insemination. *Fertil Steril* 2006;86:642–6.
74. Balen AH, Platteau P, Andersen AN, et al. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. *BJOG* 2006;113:1195–202.
75. Souter I, Baltagi LM, Kuleta D, et al. Women, weight, and fertility: the effect of body mass index on the outcome of superovulation/intrauterine insemination cycles. *Fertil Steril* 2011;95:1042–7.
76. Steinkampf MP, Hammond KR, Nichols JE, et al. Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration. *Fertil Steril* 2003;80:99–102.
77. Shah DK, Missmer SA, Correia KF, et al. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. *J Clin Endocrinol Metab* 2014;99:1314–21.
78. Chan CC, Ng EH, Chan MM, et al. Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non-obese women. *Hum Reprod* 2003;18:2294–7.
79. Mulders AG, Laven JS, Eijkemans MJ, et al. Patient predictors for outcome of gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: a meta-analysis. *Hum Reprod Update* 2003;9:429–49.
80. Wang JX, Warnes GW, Davies MJ, et al. Overweight infertile patients have a higher fecundity than normal-weight women undergoing controlled ovarian hyperstimulation with intrauterine insemination. *Fertil Steril* 2004;81:1710–2.
81. McKnight KK, Nodler JL, Cooper JJ Jr, et al. Body mass index-associated differences in response to ovulation induction with letrozole. *Fertil Steril* 2011;96:1206–8.
82. Isa AM, Abu-Rafea B, Alasiri SA, et al. Age, body mass index, and number of previous trials: are they prognosticators of intra-uterine-insemination for infertility treatment? *Int J Fertil Steril* 2014;8:255–60.
83. Fedorcak P, Dale PO, Storeng R, et al. Impact of overweight and underweight on assisted reproduction treatment. *Hum Reprod* 2004;19:2523–8.
84. Shah DK, Missmer SA, Berry KF, et al. Effect of obesity on oocyte and embryo quality in women undergoing in vitro fertilization. *Obstet Gynecol* 2011;118:63–70.
85. Pinborg A, Gaarslev C, Hougaard CO, et al. Influence of female bodyweight on IVF outcome: a longitudinal multicentre cohort study of 487 infertile couples. *Reprod Biomed Online* 2011;23:490–9.
86. Luke B, Brown MB, Stern JE, et al. Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates. *Hum Reprod* 2011;26:245–52.
87. Zhang D, Zhu Y, Gao H, et al. Overweight and obesity negatively affect the outcomes of ovarian stimulation and in vitro fertilisation: a cohort study of 2628 Chinese women. *Gynecol Endocrinol* 2010;26:325–32.
88. Dechaud H, Anahory T, Reyftmann L, et al. Obesity does not adversely affect results in patients who are undergoing in vitro fertilization and embryo transfer. *Eur J Obstet Gynecol Reprod Biol* 2006;127:88–93.
89. Maheshwari A, Stofberg L, Bhattacharya S. Effect of overweight and obesity on assisted reproductive technology—a systematic review. *Hum Reprod Update* 2007;13:433–44.
90. Zander-Fox DL, Henshaw R, Hamilton H, et al. Does obesity really matter? The impact of BMI on embryo quality and pregnancy outcomes after IVF in women aged \leq 38 years. *Aust N Z J Obstet Gynaecol* 2012;52:270–6.
91. Dokras A, Baredziak L, Blaine J, et al. Obstetric outcomes after in vitro fertilization in obese and morbidly obese women. *Obstet Gynecol* 2006;108:61–9.
92. Petersen GL, Schmidt L, Pinborg A, et al. The influence of female and male body mass index on live births after assisted reproductive technology treatment: a nationwide register-based cohort study. *Fertil Steril* 2013;99:1654–62.
93. Bellver J, Ayllon Y, Ferrando M, et al. Female obesity impairs in vitro fertilization outcome without affecting embryo quality. *Fertil Steril* 2010;93:447–54.
94. Moragianni VA, Jones SM, Ryley DA. The effect of body mass index on the outcomes of first assisted reproductive technology cycles. *Fertil Steril* 2012;98:102–8.
95. Jungheim ES, Lanzendorf SE, Odem RR, et al. Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome. *Fertil Steril* 2009;92:256–61.
96. Sathya A, Balasubramanyam S, Gupta S, et al. Effect of body mass index on in vitro fertilization outcomes in women. *J Hum Reprod Sci* 2010;3:135–8.
97. Legge A, Bouzayen R, Hamilton L, et al. The impact of maternal body mass index on in vitro fertilization outcomes. *J Obstet Gynaecol Can* 2014;36:613–9.

98. Schliep KC, Mumford SL, Ahrens KA, et al. Effect of male and female body mass index on pregnancy and live birth success after in vitro fertilization. *Fertil Steril* 2015;103:388–95.
99. Haghghi Z, Rezaei Z, Es-Haghi Ashtiani S. Effects of women's body mass index on in vitro fertilization success: a retrospective cohort study. *Gynecol Endocrinol* 2012;28:536–9.
100. Vilarino FL, Christofolini DM, Rodrigues D, et al. Body mass index and fertility: is there a correlation with human reproduction outcomes? *Gynecol Endocrinol* 2011;27:232–6.
101. Provost MP, Acharya KS, Acharya CR, et al. Pregnancy outcomes decline with increasing body mass index: analysis of 239,127 fresh autologous in vitro fertilization cycles from the 2008–2010 Society for Assisted Reproductive Technology registry. *Fertil Steril* 2016;105:663–9.
102. Leary C, Leese HJ, Sturmey RG. Human embryos from overweight and obese women display phenotypic and metabolic abnormalities. *Hum Reprod* 2015;30:122–32.
103. Metwally M, Cutting R, Tipton A, et al. Effect of increased body mass index on oocyte and embryo quality in IVF patients. *Reprod Biomed Online* 2007;15:532–8.
104. Bellver J, De Los Santos MJ, Alama P, et al. Day-3 embryo metabolomics in the spent culture media is altered in obese women undergoing in vitro fertilization. *Fertil Steril* 2015;103:1407–15, e1.
105. Bellver J, Mifsud A, Grau N, et al. Similar morphokinetic patterns in embryos derived from obese and normoweight infertile women: a time-lapse study. *Hum Reprod* 2013;28:794–800.
106. Bellver J, Pellicer A, Garcia-Velasco JA, et al. Obesity reduces uterine receptivity: clinical experience from 9,587 first cycles of ovum donation with normal weight donors. *Fertil Steril* 2013;100:1050–8.
107. Goldman KN, Hodes-Wertz B, McCulloh DH, et al. Association of body mass index with embryonic aneuploidy. *Fertil Steril* 2015;103:744–8.
108. Metwally M, Tuckerman EM, Laird SM, et al. Impact of high body mass index on endometrial morphology and function in the peri-implantation period in women with recurrent miscarriage. *Reprod Biomed Online* 2007;14:328–34.
109. Styne-Gross A, Elkind-Hirsch K, Scott RT Jr. Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation. *Fertil Steril* 2005;83:1629–34.
110. Jungheim ES, Schon SB, Schulte MB, et al. IVF outcomes in obese donor oocyte recipients: a systematic review and meta-analysis. *Hum Reprod* 2013;28:2720–7.
111. Coyne K, Whigham LD, O'Leary K, et al. Gestational carrier BMI and reproductive, fetal and neonatal outcomes: are the risks the same with increasing obesity? *Int J Obes (Lond)* 2016;40:171–5.
112. Bellver J, Melo MA, Bosch E, et al. Obesity and poor reproductive outcome: the potential role of the endometrium. *Fertil Steril* 2007;88:446–51.
113. DeUgarte DA, DeUgarte CM, Sahakian V. Surrogate obesity negatively impacts pregnancy rates in third-party reproduction. *Fertil Steril* 2010;93:1008–10.
114. Cardozo ER, Karmon AE, Gold J, et al. Reproductive outcomes in oocyte donation cycles are associated with donor BMI. *Hum Reprod* 2016;31:385–92.
115. Metwally M, Ong KJ, Ledger WL, et al. Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the evidence. *Fertil Steril* 2008;90:714–26.
116. Boots CE, Bernardi LA, Stephenson MD. Frequency of euploid miscarriage is increased in obese women with recurrent early pregnancy loss. *Fertil Steril* 2014;102:455–9.
117. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. *BMJ* 2000;320:1708–12.
118. Kaye L, Sueldo C, Engmann L, et al. Survey assessing obesity policies for assisted reproductive technology in the United States. *Fertil Steril* 2016;105:703–6, e2.
119. Hahn KA, Hatch EE, Rothman KJ, et al. Body size and risk of spontaneous abortion among danish pregnancy planners. *Paediatr Perinat Epidemiol* 2014;28:412–23.
120. Lashen H, Fear K, Sturdee DW. Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. *Hum Reprod* 2004;19:1644–6.
121. Metwally M, Saravelos SH, Ledger WL, et al. Body mass index and risk of miscarriage in women with recurrent miscarriage. *Fertil Steril* 2010;94:290–5.
122. Feig DS, Hwee J, Shah BR, et al. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996–2010. *Diabetes Care* 2014;37:1590–6.
123. Nerenberg KA, Johnson JA, Leung B, et al. Risks of gestational diabetes and preeclampsia over the last decade in a cohort of Alberta women. *J Obstet Gynaecol Can* 2013;35:986–94.
124. Schummers L, Hutcheon JA, Bodnar LM, et al. Risk of adverse pregnancy outcomes by prepregnancy body mass index: a population-based study to inform prepregnancy weight loss counseling. *Obstet Gynecol* 2015;125:133–43.
125. Marchi J, Berg M, Dencker A, et al. Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews. *Obes Rev* 2015;16:621–38.
126. Sanabria-Martínez G, García-Hermoso A, Poyatos-León R, et al. Effectiveness of physical activity interventions on preventing gestational diabetes mellitus and excessive maternal weight gain: a meta-analysis. *BJOG* 2015;122:1167–74.
127. Poston L, Bell R, Croker H, et al. Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol* 2015;3:767–77.
128. Lutsiv O, Mah J, Beyene J, et al. The effects of morbid obesity on maternal and neonatal health outcomes: a systematic review and meta-analyses. *Obes Rev* 2015;16:531–46.
129. Norman SM, Tuuli MG, Odibo AO, et al. The effects of obesity on the first stage of labor. *Obstet Gynecol* 2012;120:130–5.
130. Kobayashi N, Lim BH. Induction of labour and intrapartum care in obese women. *Best Pract Res Clin Obstet Gynaecol* 2015;29:394–405.
131. Bogaerts A, Witters I, Van den Bergh BRH, et al. Obesity in pregnancy: altered onset and progression of labour. *Midwifery* 2013;29:1303–13.
132. Weiss JL, Malone FD, Emig D, et al. Obesity, obstetric complications and cesarean delivery rate—a population-based screening study. *Am J Obstet Gynecol* 2004;190:1091–7.
133. Calderon AC, Quintana SM, Marcolin AC, et al. Obesity and pregnancy: a transversal study from a low-risk maternity. *BMC Pregnancy Childbirth* 2014;14:249.
134. Anderson V, Chaboyer W, Gillespie B. The relationship between obesity and surgical site infections in women undergoing caesarean sections: an integrative review. *Midwifery* 2013;29:1331–8.

135. Hilden K, Hanson U, Persson M, et al. Overweight and obesity: a remaining problem in women treated for severe gestational diabetes. *Diabet Med* 2016.
136. Harper A. Reducing morbidity and mortality among pregnant obese. *Best Pract Res Clin Obstet Gynaecol* 2015;29:427–37.
137. Johnsson IW, Haglund B, Ahlsson F, et al. A high birth weight is associated with increased risk of type 2 diabetes and obesity. *Pediatr Obes* 2015;10:77–83.
138. Fadl H, Magnuson A, Ostlund I, et al. Gestational diabetes mellitus and later cardiovascular disease: a Swedish population based case-control study. *BJOG* 2014;121:1530–6.
139. Lawlor DA, Lichtenstein P, Langstrom N. Association of maternal diabetes mellitus in pregnancy with offspring adiposity into early adulthood: sibling study in a prospective cohort of 280,866 men from 248,293 families. *Circulation* 2011;123:258–65.
140. Waller DK, Shaw GM, Rasmussen SA, et al. Prepregnancy obesity as a risk factor for structural birth defects. *Arch Pediatr Adolesc Med* 2007;161:745–50.
141. Correa A, Marcinkavage J. Prepregnancy obesity and the risk of birth defects: an update. *Nutr Rev* 2013;71:S68–77.
142. Chitayat D, Matsui D, Amitai Y, et al. Folic acid supplementation for pregnant women and those planning pregnancy: 2015 update. *J Clin Pharmacol* 2016;56:170–5.
143. ACOG practice bulletin no 156: obesity in pregnancy. *Obstet Gynecol* 2015;126:e112–26.
144. Lau DC, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. *CMAJ* 2007;176:S1–13.
145. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. *Physiol Rev* 2013;93:359–404.
146. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. *Endocr Rev* 2002;23:201–29.
147. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *JAMA* 2003;289:76–9.
148. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. *BMC Public Health* 2009;9:88.
149. Schmiegelow MD, Andersson C, Kober L, et al. Associations between body mass index and development of metabolic disorders in fertile women—a nationwide cohort study. *J Am Heart Assoc* 2014;3:e000672.
150. Gregg EW, Cheng YJ, Narayan KM, et al. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976–2004. *Prev Med* 2007;45:348–52.
151. Nguyen NT, Nguyen XM, Lane J, et al. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999–2006. *Obes Surg* 2011;21:351–5.
152. Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. *JAMA* 2015;314:1021–9.
153. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. *Obes Res* 2000;8:605–19.
154. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. *Lancet* 2005;366:1640–9.
155. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364:937–52.
156. Torres ML, Weaver AL, Kumar S, et al. Risk factors for developing endometrial cancer after benign endometrial sampling. *Obstet Gynecol* 2012;120:998–1004.
157. Lacey JV Jr, Chia VM, Rush BB, et al. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. *Int J Cancer* 2012;131:1921–9.
158. Heller DS, Mosquera C, Goldsmith LT, et al. Body mass index of patients with endometrial hyperplasia: comparison to patients with proliferative endometrium and abnormal bleeding. *J Reprod Med* 2011;56:110–2.
159. Epplein M, Reed SD, Voigt LF, et al. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. *Am J Epidemiol* 2008;168:563–70. discussion 71–6.
160. Weiss JM, Saltzman BS, Doherty JA, et al. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. *Am J Epidemiol* 2006;164:56–62.
161. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. *JAMA* 2000;284:3015–21.
162. American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. *Anesthesiology* 2014;120:268–86.
163. Grunstein RR, Stenlof K, Hedner J, et al. Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. *Int J Obes Relat Metab Disord* 1995;19:410–8.
164. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med* 2007;357:741–52.
165. Drager LF, Togeiro SM, Polotsky VY, et al. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. *J Am Coll Cardiol* 2013;62:569–76.
166. Marshall NS, Delling L, Grunstein RR, et al. Self-reported sleep apnoea and mortality in patients from the Swedish Obese Subjects study. *Eur Respir J* 2011;38:1349–54.
167. Lau DC, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. *CMAJ* 2007;176:S1–13.
168. Rueda-Clausen CF, Ogunleye AA, Sharma AM. Health benefits of long-term weight-loss maintenance. *Annu Rev Nutr* 2015;35:475–516.
169. Karmali S, Brar B, Shi X, et al. Weight recidivism post-bariatric surgery: a systematic review. *Obes Surg* 2013;23:1922–33.
170. Peterson RE, Latendresse SJ, Bartholome LT, et al. Binge eating disorder mediates links between symptoms of depression, anxiety, and caloric intake in overweight and obese women. *J Obes* 2012;2012:407103.
171. Friedman KE, Ashmore JA, Applegate KL. Recent experiences of weight-based stigmatization in a weight loss surgery population: psychological and behavioral correlates. *Obesity (Silver Spring)* 2008;16(Suppl 2):S69–74.

172. Byrne SM, Cooper Z, Fairburn CG. Psychological predictors of weight regain in obesity. *Behav Res Ther* 2004;42:1341–56.
173. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. *Diabetes Care* 2002;25:2165–71.
174. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403.
175. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343–50.
176. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009;374:1677–86.
177. Peirson L, Douketis J, Ciliska D, et al. Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis. *CMAJ Open* 2014;2:E306–17.
178. Hennes S, Perry CM. Orlistat: a review of its use in the management of obesity. *Drugs* 2006;66:1625–56.
179. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004;27:155–61.
180. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. *Diabetes Care* 1998;21:1288–94.
181. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. *Lancet* 2009;374:1606–16.
182. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med* 2015;373:11–22.
183. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. *Curr Opin Endocrinol Diabetes Obes* 2014;21:323–9.
184. Chilton M, Dunkley A, Carter P, et al. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. *Diabetes Obes Metab* 2014;16:237–47.
185. Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2011;155:434–47.
186. Worsley R, Jane F, Robinson PJ, et al. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. *Climacteric* 2015;18:270–7.
187. McDonagh MS, Selph S, Ozpinar A, et al. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. *JAMA Pediatr* 2014;168:178–84.
188. Ghandi S, Afatoonian A, Tabibnejad N, et al. The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. *J Assist Reprod Genet* 2011;28:591–6.
189. Lim SS, Norman RJ, Clifton PM, et al. The effect of comprehensive lifestyle intervention or metformin on obesity in young women. *Nutr Metab Cardiovasc Dis* 2011;21:261–8.
190. Metwally M, Amer S, Li TC, et al. An RCT of metformin versus orlistat for the management of obese anovulatory women. *Hum Reprod* 2009;24:966–75.
191. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. *Obes Rev* 2009;10:333–41.
192. DeMaria EJ. Bariatric surgery for morbid obesity. *N Engl J Med* 2007;356:2176–83.
193. Griffith PS, Birch DW, Sharma AM, et al. Managing complications associated with laparoscopic Roux-en-Y gastric bypass for morbid obesity. *Can J Surg* 2012;55:329–36.
194. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med* 2004;351:2683–93.
195. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. *N Engl J Med* 2014;370:2002–13.
196. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. *N Engl J Med* 2012;366:1577–85.
197. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. *N Engl J Med* 2007;357:753–61.
198. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. *N Engl J Med* 2012;367:695–704.
199. Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. *Surgery* 2007;142:621–32. discussion 32–5.
200. Andreasen LA, Nilas L, Kjaer MM. Operative complications during pregnancy after gastric bypass—a register-based cohort study. *Obes Surg* 2014;24:1634–8.
201. Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? *Obes Surg* 2005;15:145–54.
202. Poitou Bernert C, Ciangura C, Coupaye M, et al. Nutritional deficiency after gastric bypass: diagnosis, prevention and treatment. *Diabetes Metab* 2007;33:13–24.
203. Beard JH, Bell RL, Duffy AJ. Reproductive considerations and pregnancy after bariatric surgery: current evidence and recommendations. *Obes Surg* 2008;18:1023–7.
204. Monson M, Jackson M. Pregnancy after bariatric surgery. *Clin Obstet Gynecol* 2016;59:158–71.
205. Siega-Riz AM, King JC. Position of the American Dietetic Association and American Society for Nutrition: obesity, reproduction, and pregnancy outcomes. *J Am Diet Assoc* 2009;109:918–27.
206. Sheiner E, Edri A, Balaban E, et al. Pregnancy outcome of patients who conceive during or after the first year following bariatric surgery. *Am J Obstet Gynecol* 2011;204:50, e1–6.
207. Kjaer MM, Nilas L. Timing of pregnancy after gastric bypass—a national register-based cohort study. *Obes Surg* 2013;23:1281–5.
208. Willis K, Lieberman N, Sheiner E. Pregnancy and neonatal outcome after bariatric surgery. *Best Pract Res Clin Obstet Gynaecol* 2015;29:133–44.

209. Aricha-Tamir B, Weintraub AY, Levi I, et al. Downsizing pregnancy complications: a study of paired pregnancy outcomes before and after bariatric surgery. *Surg Obes Relat Dis* 2012;8:434–9.
210. Johansson K, Cnattingius S, Naslund I, et al. Outcomes of pregnancy after bariatric surgery. *N Engl J Med* 2015;372:814–24.
211. Amsalem D, Aricha-Tamir B, Levi I, et al. Obstetric outcomes after restrictive bariatric surgery: what happens after 2 consecutive pregnancies? *Surg Obes Relat Dis* 2014;10:445–9.
212. Shai D, Shoham-Vardi I, Amsalem D, et al. Pregnancy outcome of patients following bariatric surgery as compared with obese women: a population-based study. *J Matern Fetal Neonatal Med* 2014;27:275–8.
213. Berlac JF, Skovlund CW, Lidegaard O. Obstetrical and neonatal outcomes in women following gastric bypass: a Danish national cohort study. *Acta Obstet Gynecol Scand* 2014;93:447–53.
214. Kjaer MM, Lauenborg J, Breum BM, et al. The risk of adverse pregnancy outcome after bariatric surgery: a nationwide register-based matched cohort study. *Am J Obstet Gynecol* 2013;208:464, e1–5.
215. Sheiner E, Balaban E, Dreier J, et al. Pregnancy outcome in patients following different types of bariatric surgeries. *Obes Surg* 2009;19:1286–92.
216. Ducarme G, Parisio L, Santulli P, et al. Neonatal outcomes in pregnancies after bariatric surgery: a retrospective multi-centric cohort study in three French referral centers. *J Matern Fetal Neonatal Med* 2013;26:275–8.
217. Clark AM, Thornley B, Tomlinson L, et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. *Hum Reprod* 1998;13:1502–5.
218. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. *J Clin Endocrinol Metab* 1999;84:1470–4.
219. Sim KA, Partridge SR, Sainsbury A. Does weight loss in overweight or obese women improve fertility treatment outcomes? A systematic review. *Obes Rev* 2014;15:839–50.
220. Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. *Hum Reprod* 2003;18:1928–32.
221. Crosignani PG, Vegetti W, Colombo M, et al. Resumption of fertility with diet in overweight women. *Reprod Biomed Online* 2002;5:60–4.
222. Sim KA, Dezarnaulds GM, Denyer GS, et al. Weight loss improves reproductive outcomes in obese women undergoing fertility treatment: a randomized controlled trial. *Clin Obes* 2014;4:61–8.
223. Kort JD, Winget C, Kim SH, et al. A retrospective cohort study to evaluate the impact of meaningful weight loss on fertility outcomes in an overweight population with infertility. *Fertil Steril* 2014;101:1400–3.
224. Milone M, De Placido G, Musella M, et al. Incidence of successful pregnancy after weight loss interventions in infertile women: a systematic review and meta-analysis of the literature. *Obes Surg* 2016;26:443–51.
225. Christofolini J, Bianco B, Santos G, et al. Bariatric surgery influences the number and quality of oocytes in patients submitted to assisted reproduction techniques. *Obesity (Silver Spring)* 2014;22:939–42.
226. Chavarro JE, Ehrlich S, Colaci DS, et al. Body mass index and short-term weight change in relation to treatment outcomes in women undergoing assisted reproduction. *Fertil Steril* 2012;98:109–16.
227. Farquhar CM, Gillett WR. Prioritising for fertility treatments—should a high BMI exclude treatment? *BJOG* 2006;113:1107–9.
228. Gillett WR, Putt T, Farquhar CM. Prioritising for fertility treatments—the effect of excluding women with a high body mass index. *BJOG* 2006;113:1218–21.
229. Dayan N, Spitzer K, Laskin CA. A focus on maternal health before assisted reproduction: results from a pilot survey of Canadian IVF medical directors. *J Obstet Gynaecol Can* 2015;37:648–55.
230. Arden MA, Duxbury AM, Soltani H. Responses to gestational weight management guidance: a thematic analysis of comments made by women in online parenting forums. *BMC Pregnancy Childbirth* 2014;14:216.
231. Pandey S, Maheshwari A, Bhattacharya S. Should access to fertility treatment be determined by female body mass index? *Hum Reprod* 2010;25:815–20.
232. Balen AH, Anderson RA. Impact of obesity on female reproductive health: British Fertility Society, Policy and Practice Guidelines. *Hum Fertil (Camb)* 2007;10:195–206.
233. Zachariah M, Fleming R, Acharya U. Management of obese women in assisted conception units: a UK survey. *Hum Fertil (Camb)* 2006;9:101–5.
234. Harris ID, Python J, Roth L, et al. Physicians' perspectives and practices regarding the fertility management of obese patients. *Fertil Steril* 2011;96:991–2.
235. Turner-McGrievy GM, Grant BL. Prevalence of body mass index and body weight cut-off points for in vitro fertilization treatment at U.S. clinics and current clinic weight loss strategy recommendations. *Hum Fertil (Camb)* 2015;18:215–9.
236. Heitmann BL, Tang-Peronard J. Psychosocial issues in female obesity. *Womens Health (Lond)* 2007;3:271–3.
237. Muennig P. The body politic: the relationship between stigma and obesity-associated disease. *BMC Public Health* 2008;8:128.
238. Laredo SE. Obesity, polycystic ovary syndrome, infertility treatment: asking obese women to lose weight before treatment increases stigmatisation. *BMJ* 2006;332:609.
239. Sneed ML, Uhler ML, Grotjan HE, et al. Body mass index: impact on IVF success appears age-related. *Hum Reprod* 2008;23:1835–9.